| Chapters |
| Chapter 1: Introduction to Regulatory Affairs |
1 |
| Chapter 2: Premarket Requirements/Dossier Requirements |
7 |
| Chapter 3: Authorization Procedures for Medicinal oducts |
15 |
| Chapter 4: Quality Systems and Inspectorate Process—Pharmaceuticals |
31 |
| Chapter 5: Pharmaceutical Postmarketing and Compliance |
43 |
| Chapter 6: High-Risk Products Derived From Biotechnology |
55 |
| Chapter 7: Generic Drug Products and Biosimilars |
69 |
| Chapter 8: Principles of Orphan Drugs |
81 |
| Chapter 9: Food Supplements and Cosmetic Products |
87 |
| Chapter 10: Veterinary Medicinal Products |
97 |
| Chapter 11: Over-the-Counter Products (OTCs |
111 |
| Chapter 12: Medical Device Premarket Requirements |
117 |
| Chapter 13: Technical and Regulatory Requirements for Medical Devices |
137 |
| Chapter 14: Postmarket Requirements for Medical Devices |
147 |
| Chapter 15: In Vitro Diagnostic Medical Devices |
153 |
| Chapter 16: Advertising and Promotion |
161 |
| Chapter 17: Compliance and Enforcement |
167 |
| Figures and Tables |
| Figure 2-1. Diagrammatic Representation of the Organization of the ICH CTD |
9 |
| Figure 3-1. Overview of a Typical Quality Risk Management Process |
20 |
| Figure 3-2. Procedure for Drug Registration |
25 |
| Figure 3-3. Mutual Recognition Procedure in the EU |
25 |
| Figure 3-4. Decentralised Procedure (DP) in the EU |
26 |
| Figure 3-5. Centralised Procedure (CP) in the EU |
27 |
| Table 4-1. Application of ICH Q7 to API Manufacturing |
36 |
| Table 5-1. Application of Process Performance and Product Quality Monitoring System Throughout the Product Lifecycle |
45 |
| Table 5-2. Application of a CAPA System Throughout the Product Lifecycle |
46 |
| Table 5-3. Application of Change Management System Throughout the Product Lifecycle |
47 |
| Table 5-4. Application of a Management Review of Process Performance and Product Quality Throughout the Product Lifecycle |
48 |
| Table 5-5. Differences Between Old and New EU Variations Regulations |
50 |
| Table 5-6. FDA Postapproval Change Reporting |
51 |
| Table 5-7. Summary of Australian Guidelines on Drug Sponsor Reporting of Adverse Drug Reactions |
52 |
| Table 7-1. Biosimilars Authorized for Marketing by the European Commission |
75 |
| Table 7-2. Some FOBs Approved by FDA as §505(b)(2) Generic Drugs |
76 |
| Table 8-1. Epidemiologic Thresholds of Orphan Diseases in Various Countries/Regions |
84 |
| Table 8-2. Overview of Different Orphan Drug Legislation |
85 |
| Table 9-1. RDAs of Vitamins and Minerals |
89 |
| Table 9-2. Dietary Reference Intakes (DRIs): Recommended Intakes for Individual, Vitamins |
90 |
| Table 9-3. Dietary Reference Intakes (DRIs): Recommended Intakes for Individuals, Elements |
91 |
| Table 9-4. Dietary Reference Intakes (DRIs): Tolerable Upper Intake Levels (UL) Vitamins |
92 |
| Table 9-5. Dietary Reference Intakes (DRIs): Tolerable Upper Intake Levels (UL), Elements |
93 |
| Figure 10-1. VICH Steering Committee |
101 |
| Figure 10-2. Information Flow in the Pharmacovigilance System |
106 |
| Table 12-1. Class A Device |
121 |
| Table 12-2. Class B Device |
122 |
| Table 12-3. Class C Device |
122 |
| Table 12-4. Class D Device |
123 |
| Table 12-5. Noninvasive Devices |
124 |
| Table 12-6. Invasive Devices |
126 |
| Table 12-7. Active Devices |
128 |
| Table 12-8. Additional Rules |
130 |
| Figure 12-1. Decision Tree Noninvasive Devices |
131 |
| Figure 12-2. Decision Tree Invasive Devices |
132 |
| Figure 12-3. Decision Tree Invasive Devices |
133 |
| Figure 12-4. Decision Tree Active Devices |
134 |
| Figure 12-5. Decision Tree Active Devices |
135 |
| Figure 12-6. Decision Tree Additional Rules |
136 |
| Figure 13-1. Premarket Use of the STED |
139 |
| Figure 13-2. Postmarket Use of the STED |
141 |
| Figure 13-3. Postmarket Use of the STED |
143 |
| Figure 13-4. Key Activities for Supplier Control |
144 |
| Figure 14-1. CAs Reporting Flowchart |
149 |
| Figure 15-1. General GHTF Classification System for IVD Medical Devices |
154 |
| Figure 15-2. Regulatory Requirements Related to the Device Risk Class |
154 |
| Table 15-1. Classification Rules for IVDs |
155 |
| Table 15-2. Classification Rules for IVD |
156 |
| Table 15-3. Class A Device |
157 |
| Table 15-4. Class B Device |
158 |
| Table 15-5. Class C Device |
158 |
| Table 15-6. Class D Device |
159 |
| Figure 17-1. Flow Chart—Overview of Typical Audit Process |
173 |